JO3118B1
(en )
2017-09-20
Compositions and methods for antibodies targeting complement protein c5
MX345909B
(en )
2017-02-22
Anti-fgfr3 antibodies and methods using same.
PH12013500933A1
(en )
2017-08-23
Methods and compositions for neural disease immunotherapy
IN2012DN03883A
(en )
2015-09-25
MX2018009945A
(en )
2020-09-02
Novel compositions and methods for the treatment of immune related diseases.
MX2011010012A
(en )
2011-12-06
Novel anti-î+-5î²1 antibodies and uses thereof.
IN2014KN00848A
(en )
2015-10-02
PH12014501427B1
(en )
2014-09-22
Anti-phf-tau antibodies and their uses
EP3725811A3
(en )
2021-01-27
Compositions for inhibiting masp-2 dependent complement activation
PH12017500864A1
(en )
2017-12-11
Anti-notch1 antibodies
PH12013502230A1
(en )
2016-01-25
Multispecific antibodies
TN2011000528A1
(en )
2013-05-24
Compositions and methods for antibodies targeting complement protein c3b
MX2013001473A
(en )
2013-04-29
Antibodies against il-18r1 and uses thereof.
MX2011014019A
(en )
2012-02-22
Diazahomoadamantane derivatives and methods of use thereof.
PH12013500616A1
(en )
2013-06-03
Antibody compositions and methods of use
JO3437B1
(en )
2019-10-20
Enhanced anti-human fractalkin antibodies and their uses
MY161868A
(en )
2017-05-15
Anti-bv8 antibodies and uses thereof
MX2012011829A
(en )
2012-12-17
Anti-polyubiquitin antibodies and methods of use.
SG178596A1
(en )
2012-04-27
Methods of treatment using anti-oxidized ldl antibodies
IN2014DN00254A
(en )
2015-06-05
SG178865A1
(en )
2012-04-27
Cartilage repair
TN2011000041A1
(en )
2012-09-05
Compositions and methods for antibodies targeting complement protein c5
CY1116623T1
(en )
2017-03-15
COMPOSITIONS AND METHODS FOR ANTI-COMPONENTS OF PROTEIN C5 SUPPLEMENT
HK1163697A
(en )
2012-09-14
Compositions and methods for antibodies targeting complement protein c3b